Literature DB >> 34750023

Diagnosis of soft tissue tumors using immunohistochemistry as a surrogate for recurrent fusion oncoproteins.

Margaret A Black1, Gregory W Charville2.   

Abstract

Soft tissue neoplasms encompass a broad spectrum of clinicopathologic manifestations. In a subset of soft tissue tumors, spanning a wide range of clinical behavior from indolent to highly aggressive, recurrent genetic translocations yield oncogenic fusion proteins that drive neoplastic growth. Beyond functioning as primary mechanisms of tumorigenesis, recurrent translocations represent key diagnostic features insofar as the presence of a particular oncogenic gene fusion generally points to specific tumor entities. In addition to more direct methods for identifying recurrent translocations, such as conventional cytogenetics or fluorescence in situ hybridization, immunohistochemistry for a component of the fusion oncoprotein increasingly is being used as a surrogate marker, exploiting the tendency of these fusion components to be distinctively overexpressed by translocation-bearing tumor cells. Diagnostic immunohistochemistry can also be used to identify the characteristic gene expression changes that occur downstream of oncogenic fusions. Here, we review the use of immunohistochemistry to detect surrogate markers of recurrent translocations in soft tissue tumors, focusing on the practical applications and limitations of this diagnostic approach.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Chromosomal translocation; Gene expression; Immunohistochemistry; Molecular pathology; Sarcoma; Soft tissue pathology

Mesh:

Substances:

Year:  2021        PMID: 34750023      PMCID: PMC8688262          DOI: 10.1053/j.semdp.2021.10.005

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  88 in total

1.  STAT6 is amplified in a subset of dedifferentiated liposarcoma.

Authors:  Leona A Doyle; Derrick Tao; Adrián Mariño-Enríquez
Journal:  Mod Pathol       Date:  2014-01-24       Impact factor: 7.842

2.  MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma.

Authors:  Leona A Doyle; Emely Möller; Paola Dal Cin; Christopher D M Fletcher; Fredrik Mertens; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

3.  Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein.

Authors:  M R Tanas; S Ma; F O Jadaan; C K Y Ng; B Weigelt; J S Reis-Filho; B P Rubin
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

4.  Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma.

Authors:  Florian Puls; Abbas Agaimy; Uta Flucke; Thomas Mentzel; Vaiyapuri P Sumathi; Marieke Ploegmakers; Robert Stoehr; Lars-Gunnar Kindblom; Magnus Hansson; Saskia Sydow; Elsa Arbajian; Fredrik Mertens
Journal:  Am J Surg Pathol       Date:  2020-05       Impact factor: 6.394

5.  Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.

Authors:  Gian P Dagrada; Rosalin D Spagnuolo; Valentina Mauro; Elena Tamborini; Luca Cesana; Alessandro Gronchi; Silvia Stacchiotti; Marco A Pierotti; Tiziana Negri; Silvana Pilotti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

6.  PAX7 Expression in Rhabdomyosarcoma, Related Soft Tissue Tumors, and Small Round Blue Cell Neoplasms.

Authors:  Gregory W Charville; Sushama Varma; Erna Forgó; Sarah N Dumont; Eduardo Zambrano; Jonathan C Trent; Alexander J Lazar; Matt van de Rijn
Journal:  Am J Surg Pathol       Date:  2016-10       Impact factor: 6.394

7.  Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics.

Authors:  Yin P Hung; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

8.  Nuclear beta-catenin in mesenchymal tumors.

Authors:  Tony L Ng; Allen M Gown; Todd S Barry; Maggie C U Cheang; Andy K W Chan; Dmitry A Turbin; Forrest D Hsu; Robert B West; Torsten O Nielsen
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

9.  Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma.

Authors:  Munir R Tanas; Andrea Sboner; Andre M Oliveira; Michele R Erickson-Johnson; Jessica Hespelt; Philip J Hanwright; John Flanagan; Yuling Luo; Kerry Fenwick; Rachael Natrajan; Costas Mitsopoulos; Marketa Zvelebil; Benjamin L Hoch; Sharon W Weiss; Maria Debiec-Rychter; Raf Sciot; Rob B West; Alexander J Lazar; Alan Ashworth; Jorge S Reis-Filho; Christopher J Lord; Mark B Gerstein; Mark A Rubin; Brian P Rubin
Journal:  Sci Transl Med       Date:  2011-08-31       Impact factor: 17.956

10.  Loss of expression of YAP1 C-terminus as an ancillary marker for epithelioid hemangioendothelioma variant with YAP1-TFE3 fusion and other YAP1-related vascular neoplasms.

Authors:  William J Anderson; Christopher D M Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2021-06-19       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.